Literature DB >> 2117166

Decline in pulmonary function in patients with alpha 1-antitrypsin deficiency.

T Evald1, A Dirksen, S Keittelmann, K Viskum, A Kok-Jensen.   

Abstract

Sixty-five patients with severe alpha 1-antitrypsin (AAT) deficiency (phenotype PiZ) were followed with spirometry at regular intervals of one year and a median observation period of four years. The annual decline in pulmonary function was adjusted for sex, age and height by division with the predicted normal pulmonary function. The median decline in FEV1 was 1.9% predicted/year. The rate of decline was independent of age and pulmonary function, except for patients with FEV1 below 25% of predicted normal. There was a tendency towards a slower median decline in FEV1 in ex-smokers (1.7% predicted/year) compared to smokers (3.8% predicted/year) and never-smokers (3.7% predicted/year), however, this difference was not significant (p greater than 0.01). At the time of diagnosis smokers and ex-smokers had a lower FEV1 (44 and 38% predicted) than never-smokers (85% predicted) (p less than 0.02), and smokers and ex-smokers were generally younger (median age 44 and 42 years, respectively) than never smokers (median age 55 years) (p greater than 0.1). Our data indicate that smokers as well as nonsmokers with severe AAT deficiency are at risk of developing pulmonary emphysema. The disease seems to appear later in nonsmokers, though once initiated it progresses at the same rate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117166     DOI: 10.1007/bf02718180

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  10 in total

1.  Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, PiZZ.

Authors:  M C Wu; S Eriksson
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

2.  Alpha-1-antitrypsin deficiency. Usage of alpha-1-proteinase inhibitor concentrate in replacement therapy. A symposium. November 1, 1986, San Diego, California. Proceedings.

Authors: 
Journal:  Am J Med       Date:  1988-06-24       Impact factor: 4.965

Review 3.  The Pi polymorphism: genetic, biochemical, and clinical aspects of human alpha 1-antitrypsin.

Authors:  M K Fagerhol; D W Cox
Journal:  Adv Hum Genet       Date:  1981

4.  Smoking, lung function, and alpha 1-antitrypsin deficiency.

Authors:  E D Janus; N T Phillips; R W Carrell
Journal:  Lancet       Date:  1985-01-19       Impact factor: 79.321

5.  Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z.

Authors:  C Larsson
Journal:  Acta Med Scand       Date:  1978

6.  Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms.

Authors:  M L Brantly; L D Paul; B H Miller; R T Falk; M Wu; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1988-08

7.  Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency.

Authors:  R C Hubbard; S Sellers; D Czerski; L Stephens; R G Crystal
Journal:  JAMA       Date:  1988-09-02       Impact factor: 56.272

8.  Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association.

Authors:  M J Tobin; P J Cook; D C Hutchison
Journal:  Br J Dis Chest       Date:  1983-01

Review 9.  Natural history of alpha-1-protease inhibitor deficiency.

Authors:  D C Hutchison
Journal:  Am J Med       Date:  1988-06-24       Impact factor: 4.965

10.  Distribution of alpha-1-antitrypsin (Pi) phenotypes in Denmark determined by separator isoelectric focusing in agarose gel.

Authors:  M Thymann
Journal:  Hum Hered       Date:  1986       Impact factor: 0.444

  10 in total
  8 in total

1.  Criteria for alpha 1-antitrypsin substitution.

Authors:  K Viskum; A Kok-Jensen
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 2.  Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.

Authors:  Peter C Gøtzsche; Helle Krogh Johansen
Journal:  Cochrane Database Syst Rev       Date:  2016-09-20

Review 3.  Alpha-1-antitrypsin deficiency: current concepts.

Authors:  Alan T Mulgrew; Clifford C Taggart; N Gerry McElvaney
Journal:  Lung       Date:  2007-06-12       Impact factor: 2.584

Review 4.  Alpha 1-antitrypsin. Hope on the horizon for emphysema sufferers?

Authors:  M Schwaiblmair; C Vogelmeier
Journal:  Drugs Aging       Date:  1998-06       Impact factor: 3.923

Review 5.  Systematic review of the evidence relating FEV1 decline to giving up smoking.

Authors:  Peter N Lee; John S Fry
Journal:  BMC Med       Date:  2010-12-14       Impact factor: 8.775

6.  There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements.

Authors:  James A Stockley; Robert A Stockley; Elizabeth Sapey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-29

7.  Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.

Authors:  Adriano R Tonelli; Farshid Rouhani; Ning Li; Pam Schreck; Mark L Brantly
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-12-29

8.  Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement.

Authors:  Andrea Gramegna; Stefano Aliberti; Marco Confalonieri; Angelo Corsico; Luca Richeldi; Carlo Vancheri; Francesco Blasi
Journal:  Multidiscip Respir Med       Date:  2018-10-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.